The copycat drug was launched at about a 5% discount, adding to the growing competition for the blockbuster rheumatoid arthritis drug in the U.S.
Tag Archive for: AbbVie
AbbVie’s Humira will now face lower-price competition from four new biosimilars: Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.
Drugmakers Boehringer Ingelheim, Sandoz and Organon are expected to launch their biosimilars on Saturday, adding to U.S. competition for the drug that started when Amgen released its copy in January. Germany’s Fresenius plans to release its copycat version on Monday, according to the company.
The response rate exceeded the prespecified efficacy threshold and suggests epcoritamab may hold its own against Roche’s rival CD3xCD20 bispecific Lunsumio, which won FDA approval in follicular lymphoma last year.
The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG’s experimental therapy to treat a type of advanced blood cancer, nearly a month after the approval of a rival therapy from AbbVie Inc.
Coherus BioSciences Inc.said on Thursday it had agreed to resolve a dispute over its plans to launch a lower-priced version of AbbVie Inc.’s Humira, its blockbuster rheumatoid arthritis drug.
More than 3,000 state and local governments will receive nearly $19 billion in payments from drugmakers and pharmacy chains in the most recent round of opioid settlements.
British drugmaker AstraZeneca (AZN.L) said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.
Coherus BioSciences Inc. said on Thursday it plans to launch a biosimilar of AbbVie Inc’s (ABBV.N) Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug.
With Friday’s approval, Epkinly edges out Roche’s bi-specific antibody glofitamab, which is also being proposed for diffuse large B-cell lymphoma.